NCT00266526已完成2 期
A Bicentre Open Label Randomised Pilot Study for Proof of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen Bet v 1-FV Versus a Depot Extract of Natural Birch Allergen
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
Specific immunotherapy with recombinant birch pollen allergen rBet v1-FV
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Positive RAST result to birch pollen
- •Positive Skin Prick Test reaction to birch pollen
- •positive nasal provocation test result to birch pollen extract
排除标准
- •serious chronic diseases
- •other relevant seasonal allergies
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Depigoid Birch 5000 Longterm Study in Adults and AdolescentsAllergic Rhinitis/Rhinoconjunctivitis +-Intermittent AsthmaSensitization Against Betula Alba (Birch) PollenNCT01694836Leti Pharma GmbH634
终止
1 期
Phase I/IIa Clinical Evaluation of AllerT vs Placebo in Subjects Allergic to Birch PollenAllergic RhinitisAllergyNCT01728519Anergis29
进行中（未招募）
1 期
ew treatment for apple allergy in birch pollen allergic patientsAllergy to apple in birch pollen allergic patientsEUCTR2011-001221-24-ATMedical University of Vienna60
已完成
3 期
Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic RhinoconjunctivitisBirch Pollen AllergyNCT00309062Allergopharma GmbH & Co. KG
已完成
不适用
Skin Testing With Recombinant Bet v 1 and Hypoallergenic Recombinant Bet v 1 FragmentsAtopic DermatitisNCT02098551Stefan Woehrl30